Global Anticoagulant Registry in the Field

NCT01090362 | Completed DMC

• 1 other identifier: TRI08888
• Study Type: observational
• Target: 57,250
• Locations: 34 countries
• Sites: 34

Brief Summary

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients. The registry was used to document global baseline characteristics, current treatment strategies and outcome measures. Characterisation of a number of AF sub-populations was also completed. GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).

Conditions

Atrial Fibrillation

Keywords

Atrial fibrillation; Anticoagulation; Stroke; Stroke prevention; Health Economics

Outcome Measures

Primary Outcomes (24)

• Death

  All cause mortality including cardiovascular and non-cardiovascular death

  4 months

• Death

  All cause mortality including cardiovascular and non-cardiovascular death

  8 months

• Death

  All cause mortality including cardiovascular and non-cardiovascular death

  12 months

• Death

  All cause mortality including cardiovascular and non-cardiovascular death

  16 months

• Death

  All cause mortality including cardiovascular and non-cardiovascular death

  20 months

• Death

  All cause mortality including cardiovascular and non-cardiovascular death

  24 months

• Death

  All cause mortality including cardiovascular and non-cardiovascular death

  3 years

• Death

  All cause mortality including cardiovascular and non-cardiovascular death

  4 years

• Stroke/Systemic embolism (SE)

  Stroke/SE was defined as the combined end points of ischemic stroke, and SE

  4 months

• Stroke/Systemic embolism (SE)

  Stroke/SE was defined as the combined end points of ischemic stroke, and SE

  8 months

• Stroke/Systemic embolism (SE)

  Stroke/SE was defined as the combined end points of ischemic stroke, and SE

  12 months

• Stroke/Systemic embolism (SE)

  Stroke/SE was defined as the combined end points of ischemic stroke, and SE

  16 months

• Stroke/Systemic embolism (SE)

  Stroke/SE was defined as the combined end points of ischemic stroke, and SE

  20 months

• Stroke/Systemic embolism (SE)

  Stroke/SE was defined as the combined end points of ischemic stroke, and SE

  24 months

• Stroke/Systemic embolism (SE)

  Stroke/SE was defined as the combined end points of ischemic stroke, and SE

  3 years

• Stroke/Systemic embolism (SE)

  Stroke/SE was defined as the combined end points of ischemic stroke, and SE

  4 years

• Major bleeding

  Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.

  4 months

• Major bleeding

  Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.

  8 months

• Major bleeding

  Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.

  12 months

• Major bleeding

  Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.

  16 months

• Major bleeding

  Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.

  20 months

• Major bleeding

  Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.

  24 months

• Major bleeding

  Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.

  3 years

• Major bleeding

  Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.

  4 years

Secondary Outcomes (56)

• Cerebrovascular events defined as Stroke

  4 months

• Cerebrovascular events defined as Stroke

  8 months

• Cerebrovascular events defined as Stroke

  12 months

• Cerebrovascular events defined as Stroke

  16 months

• Cerebrovascular events defined as Stroke

  20 months

Study Arms (5)

Cohort 1

Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.

Cohort 2

Cohort completed with 11,351 patients enrolled from 30 countries

Cohort 3

Cohort 3 completed with 11,139 patients enrolled globally from 32 countries

Cohort 4

Cohort 4 completed with 11,2780 patients enrolled from 35 countries.

Cohort 5

Final cohort completed with 12,186 patients enrolled.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Male and female patients newly diagnosed with atrial fibrillation (AF) who are with at least one additional risk of stroke from 18 countries globally.

You may qualify if:

• Prospective Cohort
• Written informed consent
• Age 18 years and older
• New diagnosis of non-valvular atrial fibrillation (diagnosed within the last 6 weeks) with at least one additional risk factor for stroke and regardless of therapy.
• Retrospective validation cohort
• Written informed consent
• Age 18 years and older
• Diagnosis of non-valvular AF (diagnosed 6-24 months prior to enrolment) with at least one additional risk factor for stroke and regardless of therapy.

You may not qualify if:

• No further follow-up envisaged or possible within enrolling hospital or with associated family practitioner.
• Patients with transient AF secondary to a reversible cause.
• Patients recruited in controlled clinical trials.

Sponsors & Collaborators

• Thrombosis Research Institute: lead
• Bayer: collaborator
• University of Birmingham: collaborator
• Brigham and Women's Hospital: collaborator
• Quintiles, Inc.: collaborator
• Advanced Drug and Device Services SAS: collaborator
• Apothecaries Clinical Research: collaborator

Study Sites (35)

Prof. Samuel Goldhaber

Boston, Massachusetts, 02115, United States

Location

Dr Hector Luciardi, National Co-ordinating Investigator, National University of Tucuman

San Miguel de Tucumán, Argentina

Location

Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital

Melbourne, Australia

Location

Marianne Brodmann: National Co-ordinating Investigator, Medizinische Universität Graz

Graz, Austria

Location

Dr Frank Cools, National Co-ordinating Investigator, AZ Klina

Brasschaat, Belgium

Location

Dr Antonio Barretto, National Coordinating Investigator, Hospital Santa Marcelina,

São Paulo, Brazil

Location

Prof Stuart Connolly and Dr John Eikelboom, National Coodinating Investigators, Mc Master University

Hamilton, Canada

Location

Dr Ramon Corbalan, National Coordinating Investigator, Pontifica Universidad Catolica de Chile

Santiago, Chile

Location

Prof Zin-Cheng, National Coordinating Investigator, Peking Union Medical College & Chinese Academy Medical Sciences People Hospital

Beijing, China

Location

Dr Petr Jansky, National Coordinating Investigator, Cardiovaskular Center, Motol Univesity Hospital

Prague, Czechia

Location

Prof Joern Dalsgaard Nielsen, National Coordinating Investigator, Bispebjerg & Frederiksberg Hospitals

Frederiksberg, Denmark

Location

Dr. Hany Ragy, National Coordinating Investigator, Hayat Hospital

Cairo, Egypt

Location

Prof Pekka Raatikainen, National Coordinating Investigator, Univesrsity of Tampere

Tampere, Finland

Location

Prof. Jean-Yues LeHeuzey, National Coordinating Investigator, Hopital Europeen Georges Pompidou

Paris, France

Location

Prof Harald Darius, National oordinating Investigator, Vivantes Klinikum Neukölln

Berlin, Germany

Location

Dr Matyas Keltai, National Coordinating Investigator, Hungarian Institute of Cardiology

Budapest, Hungary

Location

Dr Sawney, National Coordinating Investigator, Sir Ganga Ram Hospital, New Delhi

Bangalore, India

Location

Profs Giancarlo Agnelli and Giuseppe Ambrosio, National Coordinating Investigators, University of Perugia

Perugia, Italy

Location

Professor Yukihiro Koretsune, National Coordinating Investigator, Osaka National Hospital

Osaka, Japan

Location

Dr Carlos Jerjes Sanchez Diaz, National Coordinating Investigator,Tecnologico de Monterrey

Monterrey, Mexico

Location

Professor Hugo ten Cate, National Coordinating Investigator, Cardiovascular Research Institute Maastricht

Maastricht, Netherlands

Location

Professor Dan Atar, National Coordinating Investigator, Oslo University Hospital

Oslo, Norway

Location

Prof Janina Stępińska, National Coordinating Investigator, Institute of Cardiology, Warsaw

Warsaw, Poland

Location

Professor Elizaveta Panchenko, National Coordinating Investigator, Cardiology Research and Production Center

Moscow, Russia

Location

Dr Toon Wei Lim, National Coordinating Investigator, National University Hospital

Singapore, Singapore

Location

Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand

Johannesburg, South Africa

Location

Prof. Seil Oh, National Coordinating Investigator, National University Hospital

Seoul, South Korea

Location

Dr Xavier Vinolas, National Coordinating Investigator, Hospital Santa Creu y San Pau

Barcelona, Spain

Location

Dr Marten Rosenqvist, National Coordinating Investigator, Karolinska Institute

Stockholm, Sweden

Location

Dr Jan Steffel, National Coordinating Investigator, University Hospital

Zurich, Switzerland

Location

Prof. Pantep Angchaisuksiri, National Coordinating Investigator, Ramathibodi Hospital, Mahidol University

Bangkok, Thailand

Location

Professor Ali Oto, National Coordinating Investigator, Memorial Ankara Hospital

Ankara, Turkey (Türkiye)

Location

Prof. Alexandr Parkhomenko, National Coordinating Investigator, Strazhesko Institute of Cardiology

Kiev, Ukraine

Location

Prof. Wael Al Mahmeed, National Coordinating Investigator, SKMC Cardiac Siences

Abu Dhabi, United Arab Emirates

Location

Prof. David Fitzmaurice, National Coordinating Investigator, University of Warwick

Coventry, United Kingdom

Location

Related Publications (43)

• Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AG. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012 Jan;163(1):13-19.e1. doi: 10.1016/j.ahj.2011.09.011. Epub 2011 Nov 20.

  PMID: 22172431 BACKGROUND

• Apenteng PN, Murray ET, Holder R, Hobbs FD, Fitzmaurice DA; UK GARFIELD Investigators and GARFIELD Steering Committee. An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. BMC Cardiovasc Disord. 2013 Apr 23;13:31. doi: 10.1186/1471-2261-13-31.

  PMID: 23617744 BACKGROUND

• Aalbers J. GARFIELD: a window on the real-life treatment of atrial fibrillation - South Africa joins the GARFIELD registry. Cardiovasc J Afr. 2012 Oct;23(9):528. No abstract available.

  PMID: 23108524 BACKGROUND

• Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FW; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013 May 21;8(5):e63479. doi: 10.1371/journal.pone.0063479. Print 2013.

  PMID: 23704912 RESULT

• Cheng CY, Lian TY, Zhu XJ, Virdone S, Sun K, Camm J, Li XM, Goto S, Pieper K, Kayani G, Fang XH, Jing ZC, Kakkar AK; GARFIELD-AF Investigators. Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF. Open Heart. 2025 Feb 6;12(1):e003109. doi: 10.1136/openhrt-2024-003109.

  PMID: 39914996 DERIVED

• Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, Verheugt FWA, Bassand JP, Misselwitz F, Pereira-Barretto AC, Cools F, Gibbs H, Kakkar AK; GARFIELD-AF investigators. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025 Jan 19;12(1):e002966. doi: 10.1136/openhrt-2024-002966.

  PMID: 39832940 DERIVED

• Camm CF, Virdone S, Jerjes-Sanchez C, Oh S, Eikelboom JW, Oto A, Fox KAA, Camm AJ, Pieper KS, Goto S, Ragy H, Kakkar AK; GARFIELD-AF registry. Association of care specialty with anticoagulant prescription and clinical outcomes in newly diagnosed atrial fibrillation: Results from the GARFIELD-AF registry. Int J Cardiol. 2025 Feb 15;421:132866. doi: 10.1016/j.ijcard.2024.132866. Epub 2024 Dec 2.

  PMID: 39631531 DERIVED

• Bassand JP, Virdone S, Camm AJ, Fox KAA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Keltai M, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD-AF registry. Diabetes Obes Metab. 2023 Oct;25(10):3040-3053. doi: 10.1111/dom.15202. Epub 2023 Jul 12.

  PMID: 37435777 DERIVED

• Camm AJ, Steffel J, Virdone S, Bassand JP, Fox KAA, Goldhaber SZ, Goto S, Haas S, Turpie AGG, Verheugt FWA, Misselwitz F, Herreros RC, Kayani G, Pieper KS, Kakkar AK; GARFIELD-AF Investigators. Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF. Eur Heart J Open. 2023 May 19;3(3):oead051. doi: 10.1093/ehjopen/oead051. eCollection 2023 May.

  PMID: 37293139 DERIVED

• Yuan L, Yang L, Zhang S, Xu Z, Qin J, Shi Y, Yu P, Wang Y, Bao Z, Xia Y, Sun J, He W, Chen T, Chen X, Hu C, Zhang Y, Dong C, Zhao P, Wang Y, Jiang N, Lv B, Xue Y, Jiao B, Gao H, Chai K, Li J, Wang H, Wang X, Guan X, Liu X, Zhao G, Zheng Z, Yan J, Yu H, Chen L, Ye Z, You H, Bao Y, Cheng X, Zhao P, Wang L, Zeng W, Tian Y, Chen M, You Y, Yuan G, Ruan H, Gao X, Xu J, Xu H, Du L, Zhang S, Fu H, Cheng X. Development of a tongue image-based machine learning tool for the diagnosis of gastric cancer: a prospective multicentre clinical cohort study. EClinicalMedicine. 2023 Feb 6;57:101834. doi: 10.1016/j.eclinm.2023.101834. eCollection 2023 Mar.

  PMID: 36825238 DERIVED

• van Husen G, Virdone S, Pieper K, Kayani G, Fox KAA. Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis. Eur Heart J Digit Health. 2022 Mar 25;3(2):181-194. doi: 10.1093/ehjdh/ztac011. eCollection 2022 Jun.

  PMID: 36713019 DERIVED

• Fox KAA, Virdone S, Bassand JP, Camm AJ, Goto S, Goldhaber SZ, Haas S, Kayani G, Koretsune Y, Misselwitz F, Oh S, Piccini JP, Parkhomenko A, Sawhney JPS, Stepinska J, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF investigators*. Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. BMJ Open. 2022 Jan 7;12(1):e049933. doi: 10.1136/bmjopen-2021-049933.

  PMID: 34996784 DERIVED

• Pope MK, Hall TS, Schirripa V, Radic P, Virdone S, Pieper KS, Le Heuzey JY, Jansky P, Fitzmaurice DA, Cappato R, Atar D, Camm AJ, Kakkar AK; GARFIELD-AF investigators. Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. BMJ. 2021 Oct 27;375:e066450. doi: 10.1136/bmj-2021-066450.

  PMID: 34706884 DERIVED

• Cools F, Johnson D, Camm AJ, Bassand JP, Verheugt FWA, Yang S, Tsiatis A, Fitzmaurice DA, Goldhaber SZ, Kayani G, Goto S, Haas S, Misselwitz F, Turpie AGG, Fox KAA, Pieper KS, Kakkar AK; GARFIELD-AF Investigators. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry. J Thromb Haemost. 2021 Sep;19(9):2322-2334. doi: 10.1111/jth.15415. Epub 2021 Jul 23.

  PMID: 34060704 DERIVED

• Fox KAA, Virdone S, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Oto A, Misselwitz F, Piccini JP, Dalgaard F, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2022 Mar 2;8(2):214-227. doi: 10.1093/ehjqcco/qcab028.

  PMID: 33892489 DERIVED

• Pope MK, Atar D, Svilaas A, Hole T, Nielsen JD, Hintze U, Crisby M, Raatikainen P, Airaksinen KEJ, Virdone S, Pieper K, Kayani G, Le Heuzey JY, Steffel J, Stepinska J, Bassand JP, Camm AJ; GARFIELD-AF Investigators. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry. Ann Med. 2021 Dec;53(1):485-494. doi: 10.1080/07853890.2021.1893897.

  PMID: 33818226 DERIVED

• Sayin BY, Al Mahmeed W, Ragy HI, Elbahry A, Virdone S, Kakkar AK, Ersanli M, Oto A. Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study. Adv Ther. 2021 May;38(5):2391-2405. doi: 10.1007/s12325-021-01670-5. Epub 2021 Mar 27.

  PMID: 33772428 DERIVED

• Gibbs H, Freedman B, Rosenqvist M, Virdone S, Mahmeed WA, Ambrosio G, Camm AJ, Jacobson B, Jerjes-Sanchez C, Kayani G, Oto A, Panchenko E, Ragy H, Kakkar AK; GARFIELD-AF Investigators. Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening. Am J Med. 2021 Jul;134(7):893-901.e11. doi: 10.1016/j.amjmed.2021.01.017. Epub 2021 Feb 16.

  PMID: 33607088 DERIVED

• Bassand JP, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, Fox KAA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Kakkar AK. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021 Feb 23;5(4):1081-1091. doi: 10.1182/bloodadvances.2020003560.

  PMID: 33606006 DERIVED

• Camm AJ, Fox KAA, Virdone S, Bassand JP, Fitzmaurice DA, Berchuck SI, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Cappato R, Kakkar AK; GARFIELD-AF investigators. Comparative effectiveness of oral anticoagulants in everyday practice. Heart. 2021 May 26;107(12):962-970. doi: 10.1136/heartjnl-2020-318420.

  PMID: 33593994 DERIVED

• Camm AJ, Cools F, Virdone S, Bassand JP, Fitzmaurice DA, Arthur Fox KA, Goldhaber SZ, Goto S, Haas S, Mantovani LG, Kayani G, Grierson Turpie AG, Antoon Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. J Am Coll Cardiol. 2020 Sep 22;76(12):1425-1436. doi: 10.1016/j.jacc.2020.07.045.

  PMID: 32943160 DERIVED

• Bassand JP, Apenteng PN, Atar D, Camm AJ, Cools F, Corbalan R, Fitzmaurice DA, Fox KA, Goto S, Haas S, Hacke W, Jerjes-Sanchez C, Koretsune Y, Heuzey JL, Sawhney JP, Oh S, Stepinska J, Cate VT, Verheugt FW, Kayani G, Pieper KS, Kakkar AK, Garfield-Af Investigators FT. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol. 2021 Jan;17(1):19-38. doi: 10.2217/fca-2020-0014. Epub 2020 Jul 22.

  PMID: 32696663 DERIVED

• Hacke W, Bassand JP, Virdone S, Camm AJ, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AG, van Eickels M, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. Int J Stroke. 2020 Apr;15(3):308-317. doi: 10.1177/1747493019891516. Epub 2019 Dec 17.

  PMID: 31847794 DERIVED

• Atar D, Berge E, Le Heuzey JY, Virdone S, Camm AJ, Steffel J, Gibbs H, Goldhaber SZ, Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Bassand JP, Kakkar AK; GARFIELD-AF Investigators. The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. Europace. 2020 Feb 1;22(2):195-204. doi: 10.1093/europace/euz292.

  PMID: 31747004 DERIVED

• Verheugt FWA, Ambrosio G, Atar D, Bassand JP, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. Am J Med. 2019 Dec;132(12):1431-1440.e7. doi: 10.1016/j.amjmed.2019.06.008. Epub 2019 Jul 12.

  PMID: 31306621 DERIVED

• Haas S, Camm AJ, Bassand JP, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AG, Sawhney JP, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Am Heart J. 2019 Jul;213:35-46. doi: 10.1016/j.ahj.2019.03.013. Epub 2019 Apr 11.

  PMID: 31128503 DERIVED

• Corbalan R, Bassand JP, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry. JAMA Cardiol. 2019 Jun 1;4(6):526-548. doi: 10.1001/jamacardio.2018.4729.

  PMID: 31066873 DERIVED

• Jerjes-Sanchez C, Corbalan R, Barretto ACP, Luciardi HL, Allu J, Illingworth L, Pieper KS, Kayani G; GARFIELD-AF Investigators. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. Clin Cardiol. 2019 May;42(5):553-560. doi: 10.1002/clc.23176. Epub 2019 Apr 9.

  PMID: 30873623 DERIVED

• Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. J Am Heart Assoc. 2019 Feb 5;8(3):e010510. doi: 10.1161/JAHA.118.010510.

  PMID: 30717616 DERIVED

• Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation. 2019 Feb 5;139(6):787-798. doi: 10.1161/CIRCULATIONAHA.118.035012.

  PMID: 30586740 DERIVED

• Sawhney JP, Kothiwale VA, Bisne V, Durgaprasad R, Jadhav P, Chopda M, Vanajakshamma V, Meena R, Vijayaraghavan G, Chawla K, Allu J, Pieper KS, John Camm A, Kakkar AK; GARFIELD-AF Investigators. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart J. 2018 Nov-Dec;70(6):828-835. doi: 10.1016/j.ihj.2018.09.001. Epub 2018 Sep 12.

  PMID: 30580852 DERIVED

• Cools F, Wollaert B, Vervoort G, Verstraete S, Voet J, Hermans K, Heyse A, De Wolf A, Hollanders G, Boussy T, Anne W, Vercammen J, Faes D, Beutels M, Mairesse G, Purnode P, Blankoff I, Vandergoten P, Capiau L, Allu J, Bassand JP, Kayani G; GARFIELD-AF Investigators. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. Acta Cardiol. 2019 Aug;74(4):309-318. doi: 10.1080/00015385.2018.1494089. Epub 2018 Oct 27.

  PMID: 30369290 DERIVED

• Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, Fox KAA, Gao H, Goldhaber SZ, Goto S, Haas S, Kayani G, Pieper K, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One. 2018 Jan 25;13(1):e0191592. doi: 10.1371/journal.pone.0191592. eCollection 2018.

  PMID: 29370229 DERIVED

• Apenteng PN, Gao H, Hobbs FR, Fitzmaurice DA; UK GARFIELD-AF Investigators and GARFIELD-AF Steering Committee. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry. BMJ Open. 2018 Jan 13;8(1):e018905. doi: 10.1136/bmjopen-2017-018905.

  PMID: 29331969 DERIVED

• Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J. 2018 Feb 7;39(6):464-473. doi: 10.1093/eurheartj/ehx730.

  PMID: 29281086 DERIVED

• Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017 Dec 21;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.

  PMID: 29273652 DERIVED

• Fox KAA, Accetta G, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Kayani G, Kakkar AK; GARFIELD-AF Investigators. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):27-35. doi: 10.1093/ehjqcco/qcx030.

  PMID: 28950344 DERIVED

• Camm AJ, Accetta G, Al Mahmeed W, Ambrosio G, Goldhaber SZ, Haas S, Jansky P, Kayani G, Misselwitz F, Oh S, Oto A, Raatikainen P, Steffel J, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 2017 Mar 6;7(3):e014579. doi: 10.1136/bmjopen-2016-014579.

  PMID: 28264833 DERIVED

• Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One. 2016 Oct 28;11(10):e0164076. doi: 10.1371/journal.pone.0164076. eCollection 2016.

  PMID: 27792741 DERIVED

• Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017 Feb 15;103(4):307-314. doi: 10.1136/heartjnl-2016-309832. Epub 2016 Sep 19.

  PMID: 27647168 DERIVED

• Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, Misselwitz F, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Int J Cardiol. 2016 Nov 15;223:543-547. doi: 10.1016/j.ijcard.2016.08.236. Epub 2016 Aug 13.

  PMID: 27552578 DERIVED

• Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Ten Cate H, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016 Oct 7;37(38):2882-2889. doi: 10.1093/eurheartj/ehw233. Epub 2016 Jun 29.

  PMID: 27357359 DERIVED

• Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Jansky P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S12-20. doi: 10.1161/CIRCOUTCOMES.114.001556. Epub 2015 Feb 24.

  PMID: 25714828 DERIVED

Related Links

• Sponsor's website

MeSH Terms

Conditions

Atrial Fibrillation; Stroke

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases

Study Officials

• Ajay K Kakkar

  Thrombosis Research Institute, London, UK

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2010
• First Posted: March 19, 2010
• Study Start: December 21, 2009
• Primary Completion: June 16, 2019
• Study Completion: May 18, 2020
• Last Updated: April 28, 2021

Record last verified: 2021-04

Locations

DK (1); US (1); ZA (1); HU (1); AE (1); EG (1); FR (1); NO (1); IT (1); UA (1); NL (1); RU (1); TH (1); KR (1); BR (1); AU (1); ES (1); BE (1); AR (1); CZ (1); SE (1); CL (1); JP (1); TU (1); IN (1); CN (1); PL (1); CH (1); FI (1); SG (1); GB (1); CA (1); DE (1); ME (1)